ONCOGENOMICS Genomic Profiling of Bone and Soft Tissue Tumors with Supernumerary Ring Chromosomes Using Tiling Resolution Bacterial Artificial Chromosome Microarrays

Total Page:16

File Type:pdf, Size:1020Kb

ONCOGENOMICS Genomic Profiling of Bone and Soft Tissue Tumors with Supernumerary Ring Chromosomes Using Tiling Resolution Bacterial Artificial Chromosome Microarrays Oncogene (2006) 25, 7106–7116 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc ONCOGENOMICS Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays M Heidenblad1, KH Hallor1, J Staaf2,GJo¨ nsson2,A˚ Borg2,MHo¨ glund1, F Mertens1 and N Mandahl1 1Department of Clinical Genetics, Lund University Hospital, Lund, Sweden; and 2Department of Oncology, Lund University Hospital, Lund, Sweden Ring chromosomes and/or giant marker chromosomes Keywords: sarcoma; array-based CGH; genome-wide; have been observed in a variety of human tumor types, but gene amplification; ring chromosome they are particularly common in a subgroup of mesen- chymal tumors of low-grade or borderline malignancy. These rings and markers have been shown to contain amplified material predominantly from 12q13–15, but also sequences from other chromosomes. Such amplified Introduction sequences were mapped in detail by genome-wide array comparative genomic hybridization in ring-containing Several bone and soft tissue tumor entities are characte- tumor samples from soft tissue (n ¼ 15) and bone rized cytogenetically by supernumerary ring chromosomes (n ¼ 6), using tiling resolution microarrays, encompassing or giant rod marker chromosomes in karyotypes with 32 433 bacterial artificial chromosome clones. The DNA few or no other chromosome aberrations (Mitelman copy number profiles revealed multiple amplification et al., 2005). The majority of these tumors are low-grade targets, in many cases highly discontinuous, leading to malignant neoplasms that include well-differentiated delineation of large numbers of very small amplicons. A liposarcoma/atypical lipomatous tumor (ALT), subgroups total number of 356 (median size: 0.64 Mb) amplicons of malignant fibrous histiocytoma (MFH), myxofibro- were seen in the soft tissue tumors and 90 (median size: sarcoma, parosteal osteosarcoma and dermatofibrosar- 1.19 Mb) in the bone tumors. Notably, more than 40% of coma protuberans (DFSP). The origin of the ring all amplicons in both soft tissue and bone tumors were chromosomes, which frequently vary in number and mapped to chromosome 12, and at least one of the size between cells from the same tumor, cannot be previously reported recurrent amplifications in 12q13.3– disclosed by chromosome banding techniques owing 14.1 and 12q15.1, including SAS and CDK4, and MDM2, to the diffuse banding pattern and morphological respectively, were present in 85% of the soft tissue tumors variability. Fluorescence in situ hybridization (FISH) and in all of the bone tumors. Although chromosome 12 analyses have revealed that these structures, in most was the only chromosome displaying recurrent amplifica- cases, contain material from chromosome 12, apart tion in the bone tumors, the soft tissue tumors frequently from in DFSP where chromosome 17 and 22 sequences, showed recurrent amplicons mapping to other chromo- including the PDGFB/COL1A1 fusion gene, are present somes, that is, 1p32, 1q23–24, 3p11–12, 6q24–25 and in rings (Dal Cin et al., 1993; Szymanska et al., 1996; 20q11–12. Of particular interest, amplicons containing Chibon et al., 2002; Sirvent et al., 2003). With few excep- genes involved in the c-jun NH2-terminal kinase/mitogen- tions, it is the central part of the long-arm of chromo- activated protein kinase pathway, that is, JUN in 1p32 some 12 (12q) that is present in multiple copies in the ONCOGENOMICS and MAP3K7IP2 (TAB2) in 6q24–25, were found to be ring chromosomes. The amplifications may be discon- independently amplified in eight of 11 cases with 12q tinuous and vary in size, but frequently include chromo- amplification, providing strong support for the notion that some bands 12q14 and 12q15 (Berner et al., 1996). The aberrant expression of this pathway is an important step MDM2 gene is always amplified, whereas several other in the dedifferentiation of liposarcomas. genes, such as SAS, GLI, CDK4 and HMGA2, are Oncogene (2006) 25, 7106–7116. doi:10.1038/sj.onc.1209693; frequently coamplified (Meltzer et al., 1991; Nilbert published online 29 May 2006 et al., 1994; Pedeutour et al., 1994; Gamberi et al., 2000; Gisselsson et al., 2002). The composition of the ring and giant marker Correspondence: Dr M Heidenblad, Department of Clinical Genetics, chromosomes is often quite complex and may include Lund University Hospital, Lund SE-221 85, Sweden. E-mail: markus.heidenblad@med.lu.se material from two or more chromosomes. Apart Received 3 January 2006; revised 3 March 2006; accepted 18 April 2006; from the inclusion of chromosome 12 material, direct published online 29 May 2006 evidence through FISH analysis has shown that a Genomic profiling of bone and soft tissue tumors M Heidenblad et al 7107 variety of chromosomes may be involved, in particular amplicons per sample). The number of chromosomes chromosome 1 (Pedeutour et al., 1994; Forus et al., involved in amplification in each case varied from 1 to 1995a; Meza-Zepeda et al., 2001; Nilsson et al., 2004). 14 (case 9); only chromosome 4 was never involved. Similarly, indirect evidence has been obtained from Analysis of primary tumor data from all 19 patients on chromosome-based comparative genomic hybridization average indicated a higher amplification frequency in the (CGH) (Pedeutour et al., 1999; Chibon et al., 2002; soft tissue tumors than in the bone tumors (23 vs 15 Micci et al., 2002; Coindre et al., 2004). The profiles of amplicons per case). Moreover, the analysis showed that genomic imbalances show many similarities between amplicon sizes were significantly smaller among the ALT, dedifferentiated liposarcoma (DDLS) and MFH, former (median size: 0.64 Mb) than among the latter which all share amplification of 12q14–15 in practically (median size: 1.19 Mb; Po0.01, Mann–Whitney U-test). all cases, and in which gain of 1q21–23 is common. Neither the number nor the distribution of amplicons However, also some distinct differences have been distinguished the four soft tissue tumors that meta- reported (Chibon et al., 2002). For example, gain of stasized from those that did not, or the high-grade from sequences from 1p32, 6q23 and 12q24 were absent or the low-grade osteosarcomas. very rare in ALT but fairly common among the other Regarding the genomic localization of the amplicons, soft tissue tumor types. Available data indicate a consi- chromosome 12 was by far most frequently affected derable biological overlap between low-grade MFH (17 of 19 cases), harboring more than 40% of the and lipomatous tumors (Chibon et al., 2002; Coindre amplicons in both tumor groups. In the soft tissue et al., 2003). Based on chromosome CGH data, the 12q tumors, also chromosomes 1 and 6 were commonly amplicon extends from 12q13 to 12q21 in most cases, affected, containing 25 and 6% of the amplicons in with a peak in 12q14 and 12q15, but may occasionally this group, respectively. Apart from chromosome 12, include both more distal and more proximal regions. the only chromosome amplified in more than one bone The 1q amplicon is usually located between 1q21 and tumor was chromosome 5. However, this chromo- 1q25 with a peak incidence in 1q23, whereas the 1p some did not contain any overlapping amplicons. A amplicon seems to be narrow and commonly includes complete description of all amplicons is available only 1p32. in Supplementary Table 1. In the present study, soft tissue and bone tumors To identify genomic regions likely to contain genes of with ring and/or giant marker chromosomes and few or importance for tumor development, a list of recurrent no other chromosome aberrations were investigated by amplifications was compiled (Table 2). In the soft tissue array CGH. For this purpose we used whole-genome tumors, segments amplified in 2–11 of 13 cases were tiling resolution bacterial artificial chromosome (BAC) identified in 1p, 1q, 3p, 6q, 12p, 12q and 20q. Because of microarrays, encompassing 32 433 BAC clones. To the high amplification occurrence and complex distri- determine whether any association between patterns of bution within chromosomes 1 and 12 in this group, DNA copy number alterations and tumor histotype amplification frequency plots were generated for these could be detected, tumors with several different diag- chromosomes (Figure 3a and b). The profile for noses were included in the investigation. chromosome 1 showed a distinct peak in 1p32, indicat- ing a recurrently amplified region of 1.18 Mb that contains four annotated genes, including JUN (Table 2). In 1q, three frequently amplified regions, all located Results within 1q23.2–1q24.3, were detected. The chromosome 12 profile revealed two narrow peaks of amplification The array CGH analysis revealed DNA copy number in 12q13.3–14.1 and 12q15, respectively, affected in alterations in all 13 soft tissue tumors and in all six bone more than 60% of the soft tissue tumors. The proximal tumors (Figure 1a, Table 1). Although several single- 0.42 Mb region contains 17 genes, including SAS and copy gains and losses of larger chromosomal segments CDK4, and the distal 0.75 Mb region comprises 16 were observed, the copy number changes were domi- genes, including MDM2. Other, less frequent, recurrent nated by genomic amplifications. As a lot of these amplifications in the soft tissue tumors were seen in demonstrated highly discontinuous patterns, large num- 3p11.1–12.1, 6q24.3–25.1 and 20q11.2–12.1 (Table 2). bers of very small amplicons were seen in the majority of The only chromosome showing overlapping amplifi- cases. In many instances, the amplification levels were cations in the bone tumors was chromosome 12. The higher than fivefold, including extreme cases in which amplification analysis revealed three small regions in more than 30-fold amplification were observed. Even 12p, all amplified in two of six cases (Table 2). The most though individual amplicons were dispersed throughout distal segment, located in 12p13.3, is 0.62 Mb in size and most of the genome, marked aggregations were observed contains seven genes, including CCND2, FGF6 and in specific chromosomes, mainly 1 and 12 (Figures 1 and FGF23.
Recommended publications
  • Tak1 Polyclonal Antibody Catalog # AP72719
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Tak1 Polyclonal Antibody Catalog # AP72719 Specification Tak1 Polyclonal Antibody - Product Information Application IF Primary Accession O43318 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Tak1 Polyclonal Antibody - Additional Information Gene ID 6885 Other Names MAP3K7; TAK1; Mitogen-activated protein kinase kinase kinase 7; Transforming growth factor-beta-activated kinase 1; TGF-beta-activated kinase 1 Dilution IF~~IF: 1:50-200 Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/40000. Not yet tested in other applications. Format Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Storage Conditions -20℃ Tak1 Polyclonal Antibody - Protein Information Name MAP3K7 {ECO:0000303|PubMed:28397838, ECO:0000312|HGNC:HGNC:6859} Function Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7.
    [Show full text]
  • Wo 2010/075007 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075007 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) G06F 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/067757 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 11 December 2009 ( 11.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12/3 16,877 16 December 2008 (16.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): DODDS, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, W., Jean [US/US]; 938 Stanford Street, Santa Monica, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, CA 90403 (US).
    [Show full text]
  • Genome-Wide Analysis of Host-Chromosome Binding Sites For
    Lu et al. Virology Journal 2010, 7:262 http://www.virologyj.com/content/7/1/262 RESEARCH Open Access Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Fang Lu1, Priyankara Wikramasinghe1, Julie Norseen1,2, Kevin Tsai1, Pu Wang1, Louise Showe1, Ramana V Davuluri1, Paul M Lieberman1* Abstract The Epstein-Barr Virus (EBV) Nuclear Antigen 1 (EBNA1) protein is required for the establishment of EBV latent infection in proliferating B-lymphocytes. EBNA1 is a multifunctional DNA-binding protein that stimulates DNA replication at the viral origin of plasmid replication (OriP), regulates transcription of viral and cellular genes, and tethers the viral episome to the cellular chromosome. EBNA1 also provides a survival function to B-lymphocytes, potentially through its ability to alter cellular gene expression. To better understand these various functions of EBNA1, we performed a genome-wide analysis of the viral and cellular DNA sites associated with EBNA1 protein in a latently infected Burkitt lymphoma B-cell line. Chromatin-immunoprecipitation (ChIP) combined with massively parallel deep-sequencing (ChIP-Seq) was used to identify cellular sites bound by EBNA1. Sites identified by ChIP- Seq were validated by conventional real-time PCR, and ChIP-Seq provided quantitative, high-resolution detection of the known EBNA1 binding sites on the EBV genome at OriP and Qp. We identified at least one cluster of unusually high-affinity EBNA1 binding sites on chromosome 11, between the divergent FAM55 D and FAM55B genes. A con- sensus for all cellular EBNA1 binding sites is distinct from those derived from the known viral binding sites, sug- gesting that some of these sites are indirectly bound by EBNA1.
    [Show full text]
  • Protein Phosphorylation Sites Notes References Transcription Factors
    Protein Phosphorylation Notes References sites Transcription AML1 Ser249, Ser266 Phosphorylation of the acute myelogenous leukemia 1 (AML1) potentially regulates its (Tanaka et al., 1996) Factors (RUNX1) transactivation potential and thereby modifies myeloid hematopoietic differentiation. Androgen Ser514 Phosphorylation of androgen receptor by ERKs is controversial. May play a role in survival (Yeh et al., 1999) receptor and proliferation of prostate cells. Arix/Phox2a Ser36, Ser71 Phosphorylation of Arix by ERK1/2 inhibits its ability to interact with target genes. (Hsieh et al., 2005) ATF2 Thr71 This phosphorylation together with the phosphorylation of Thr69 by p38MAPK induces (Ouwens et al., 2002) activation of ATF2. Beta2 (Neuro Ser274 Phosphorylation of this HLH transcription factor induces its glucose-sensitive transactivation (Khoo et al. 2003) D1) and enhances its capability to heterodimerize with E47/12 and bind to DNA. BCL-6 Ser333, Ser343 Phosphorylation of BCL-6 induces its degradation that is important for B-cell differentiation (Niu et al., 1998) and antibody response. BMAL1 Ser527, Thr534, Phosphorylation of this helix-loop-helix-PAS transcription factor inhibits its activity as a clock (Sanada et al., 2002) Ser599 (chicken) oscillator. CBP Thr188 Phosphorylation of the C-terminal region of the CREB binding protein (CBP, and also its (Janknecht and homolog p300) enhances its transactivation potential. Nordheim, 1996) C/EBPb Thr188 (rat) Phosphorylation of the CCAAT/enhancer-binding protein-b (C/EBPb) by ERK2 (not ERK1) (Hanlon et al., 2001) enhances its interaction with SRF and its transactivation activity. CRY1/2 Ser265, Ser557 Phosphorylation of the Cryptochromes proteins CRY1 and 2 results in attenuation of their (Sanada et al., 2004) (CRY1, mouse) ability to inhibit BMAL1:CLOCK-mediated transcription.
    [Show full text]
  • 2219.Full.Pdf
    The JNK Are Important for Development and Survival of Macrophages S. Roy Himes, David P. Sester, Timothy Ravasi, Stephen L. Cronau, Tedjo Sasmono and David A. Hume This information is current as of September 28, 2021. J Immunol 2006; 176:2219-2228; ; doi: 10.4049/jimmunol.176.4.2219 http://www.jimmunol.org/content/176/4/2219 Downloaded from References This article cites 64 articles, 40 of which you can access for free at: http://www.jimmunol.org/content/176/4/2219.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 28, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The JNK Are Important for Development and Survival of Macrophages S. Roy Himes, David P. Sester, Timothy Ravasi, Stephen L. Cronau, Tedjo Sasmono, and David A. Hume1 We report in this study that activation of the JNK by the growth factor, CSF-1 is critical for macrophage development, prolif- eration, and survival.
    [Show full text]
  • Table S1| Differential Expression Analysis of the Atopy Transcriptome
    Table S1| Differential expression analysis of the atopy transcriptome in CD4+ T-cell responses to allergens in atopic and nonatopic subjects Probe ID S.test Gene Symbol Gene Description Chromosome Statistic Location 7994280 10.32 IL4R Interleukin 4 receptor 16p11.2-12.1 8143383 8.95 --- --- --- 7974689 8.50 DACT1 Dapper, antagonist of beta-catenin, homolog 1 14q23.1 8102415 7.59 CAMK2D Calcium/calmodulin-dependent protein kinase II delta 4q26 7950743 7.58 RAB30 RAB30, member RAS oncogene family 11q12-q14 8136580 7.54 RAB19B GTP-binding protein RAB19B 7q34 8043504 7.45 MAL Mal, T-cell differentiation protein 2cen-q13 8087739 7.27 CISH Cytokine inducible SH2-containing protein 3p21.3 8000413 7.17 NSMCE1 Non-SMC element 1 homolog (S. cerevisiae) 16p12.1 8021301 7.15 RAB27B RAB27B, member RAS oncogene family 18q21.2 8143367 6.83 SLC37A3 Solute carrier family 37 member 3 7q34 8152976 6.65 TMEM71 Transmembrane protein 71 8q24.22 7931914 6.56 IL2R Interleukin 2 receptor, alpha 10p15-p14 8014768 6.43 PLXDC1 Plexin domain containing 1 17q21.1 8056222 6.43 DPP4 Dipeptidyl-peptidase 4 (CD26) 2q24.3 7917697 6.40 GFI1 Growth factor independent 1 1p22 7903507 6.39 FAM102B Family with sequence similarity 102, member B 1p13.3 7968236 5.96 RASL11A RAS-like, family 11, member A --- 7912537 5.95 DHRS3 Dehydrogenase/reductase (SDR family) member 3 1p36.1 7963491 5.83 KRT1 Keratin 1 (epidermolytic hyperkeratosis) 12q12-q13 7903786 5.72 CSF1 Colony stimulating factor 1 (macrophage) 1p21-p13 8019061 5.67 SGSH N-sulfoglucosamine sulfohydrolase (sulfamidase) 17q25.3
    [Show full text]
  • MAP3K7 (Phospho-Thr187) Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP52512
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 MAP3K7 (Phospho-Thr187) Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP52512 Specification MAP3K7 (Phospho-Thr187) Antibody - Product Information Application WB Primary Accession O43318 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Calculated MW 67196 MAP3K7 (Phospho-Thr187) Antibody - Additional Information Gene ID 6885 Other Names Mitogen-activated protein kinase kinase Western blot analysis of extracts from 3T3 kinase 7, Transforming growth factor-beta-activated kinase 1, cells, treated with heat shock, using MAP3K7 TGF-beta-activated kinase 1, MAP3K7, TAK1 (Phospho-Thr187) antibody. Dilution WB~~1:1000 Format Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.09% (W/V) sodium azide and 50% glycerol. Storage Conditions -20℃ MAP3K7 (Phospho-Thr187) Antibody - Protein Information Western blot analysis of extracts from 3T3 cells (Lane 2), A549 cells (Lane 3) and Hela cells (Lane 4), using MAP3K7 Name MAP3K7 (Phospho-Thr187) Antibody. The lane on the {ECO:0000303|PubMed:28397838, ECO:0000312|HGNC:HGNC:6859} left is treated with synthesized peptide. Function Serine/threonine kinase which acts as an MAP3K7 (Phospho-Thr187) Antibody - essential component of the MAP kinase Background signal transduction pathway. Plays an important role in the cascades of cellular Serine/threonine kinase which acts as an Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 responses evoked by changes in the essential component of the MAP kinase signal environment. Mediates signal transduction transduction pathway.
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; a.jeong@swisstph.ch (A.J.); medea.imboden@swisstph.ch (M.I.); christian.schindler@swisstph.ch (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; ghantousa@iarc.fr (A.G.); NovoloacaA@students.iarc.fr (A.N.); hercegz@iarc.fr (Z.H.); CueninC@iarc.fr (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; anneelie.carsin@isglobal.org (A.-E.C.); manolis.kogevinas@isglobal.org (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; gianfranco.lovison@unipa.it 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; R.C.H.Vermeulen@uu.nl 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; d.jarvis@imperial.ac.uk (D.J.); a.amaral@imperial.ac.uk (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Florian.Kronenberg@i-med.ac.at 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; p.vineis@imperial.ac.uk 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: nicole.probst@swisstph.ch; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • TAB2 Antibody Catalog # ASC10267
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 TAB2 Antibody Catalog # ASC10267 Specification TAB2 Antibody - Product Information Application IHC Primary Accession Q9NYJ8 Other Accession NP_055908, 14149669 Reactivity Human Host Rabbit Clonality Polyclonal Isotype IgG Application Notes TAB2 antibody can be used for detection of TAB2 by immunohistoc Immunohistochemistry of TAB2 in human hemistry at 5 brain tissue with TAB2 antibody at 5 µg/mL. µg/mL. TAB2 Antibody - Background TAB2 Antibody - Additional Information TAB2 Antibody: TAB2 is an activator of Gene ID 23118 MAP3K7/TAK1, which is required for for the IL-1 Other Names induced activation NF-kappaB and MAPK8/JNK. TAB2 Antibody: CHTD2, MAP3K7IP2, This protein forms a kinase complex with KIAA0733, TGF-beta-activated kinase 1 and TRAF6, MAP3K7 and TAB1, thus serves as an MAP3K7-binding protein 2, adaptor linking MAP3K7 and TRAF6. This Mitogen-activated protein kinase kinase protein, TAB1, and MAP3K7 also participate in kinase 7-interacting protein 2, TAB-2, the signal transduction induced by TGF-beta activated kinase 1/MAP3K7 TNFSF11/RANKL through the activation of the binding protein 2 receptor activator of NF-kappaB (TNFRSF11A/RANK), which may regulate the Target/Specificity development and function of osteoclasts. TAB2; TAB2 antibody is human specific. Recent experiments have shown that TAB2 and TAB2 antibody is predicted not to cross-react with other TAB proteins. the related protein TAB3 constitutitvely interact with the autophagy mediator Beclin-1; Reconstitution & Storage upon induction of autophagy, these proteins TAB2 antibody can be stored at 4℃ for dissociate from Beclin-1 and bind TAK1.
    [Show full text]
  • MAP3K7 Antibody Purified Mouse Monoclonal Antibody Catalog # Ao2028a
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 MAP3K7 Antibody Purified Mouse Monoclonal Antibody Catalog # AO2028a Specification MAP3K7 Antibody - Product Information Application WB, E Primary Accession O43318 Reactivity Human Host Mouse Clonality Monoclonal Isotype IgG2a Calculated MW 67.2kDa KDa Description The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase mediates the signaling transduction induced by TGF beta and morphogenetic protein (BMP), and controls a variety of cell functions including transcription regulation and apoptosis. In response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2; this complex is required for the activation of nuclear factor kappa B. This kinase can also activate MAPK8/JNK, MAP2K4/MKK4, and thus plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. Immunogen Purified recombinant fragment of human MAP3K7 (AA: 471-579) expressed in E. Coli. Formulation Purified antibody in PBS with 0.05% sodium azide and 0.5% protein stabilizer MAP3K7 Antibody - Additional Information Gene ID 6885 Other Names Mitogen-activated protein kinase kinase kinase 7, 2.7.11.25, Transforming growth factor-beta-activated kinase 1, TGF-beta-activated kinase 1, MAP3K7, TAK1 Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Dilution WB~~1/500 - 1/2000 E~~1/10000 Storage Maintain refrigerated at 2-8°C for up to 6 months.
    [Show full text]
  • Association of SUMO4 M55V and -94Ins/Del Gene Variants with Type-2 Diabetes
    in vivo 28: 919-924 (2014) Association of SUMO4 M55V and -94Ins/Del Gene Variants with Type-2 Diabetes SEYMA SOZEN1, CEM HOROZOGLU1, ELIF SINEM BIRELLER1, ZEYNEP KARAALI2 and BEDIA CAKMAKOGLU1 1Department of Molecular Medicine, Institute for Experimental Medicine Research, Istanbul University, Istanbul, Turkey; 2Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey Abstract. Aim: There are two different types of diabetes suggested a common underlying genetic basis (2, 3). To date, mellitus, type 1 and type 2, with still unclear molecular only some shared susceptibility genes have been reported. mechanisms. In the present study, we aimed to investigate the Ikegami and Ogihara have indicated that type-1 diabetes is role of small ubiquitin-like modifier 4 (SUMO4) M55V and the result of an absolute loss of endogenous insulin due to nuclear factor kappa B1 (NFKB1)-94del/ins in type-2 its autoimmune destruction of insulin-producing cells of the diabetes mellitus. Materials and Methods: We analyzed pancreas, whereas type-2 diabetes occurs due to de-regulated SUMO4 M55V and NFKB1-94del/ins variants in 104 insulin secretion and/or insulin sensitivity and shows patients with type-2 diabetes and 124 healthy controls using variability within each individual (1). The human leukocyte the polymerase chain reaction (PCR) and restriction antigen (HLA) region for insulin-dependent diabetes mellitus fragment length polymorphism (RFLP) techniques. Results: 1 (IDDM1), which is a major susceptibility locus for type-1 The number of SUMO4 M55V MM genotype and M allele diabetes, has also been associated with type-2 diabetes (4, carriers was significantly higher in patients compared to the 5).
    [Show full text]
  • The Human Gene Connectome As a Map of Short Cuts for Morbid Allele Discovery
    The human gene connectome as a map of short cuts for morbid allele discovery Yuval Itana,1, Shen-Ying Zhanga,b, Guillaume Vogta,b, Avinash Abhyankara, Melina Hermana, Patrick Nitschkec, Dror Friedd, Lluis Quintana-Murcie, Laurent Abela,b, and Jean-Laurent Casanovaa,b,f aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U980, Necker Medical School, 75015 Paris, France; cPlateforme Bioinformatique, Université Paris Descartes, 75116 Paris, France; dDepartment of Computer Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; eUnit of Human Evolutionary Genetics, Centre National de la Recherche Scientifique, Unité de Recherche Associée 3012, Institut Pasteur, F-75015 Paris, France; and fPediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, 75015 Paris, France Edited* by Bruce Beutler, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 15, 2013 (received for review October 19, 2012) High-throughput genomic data reveal thousands of gene variants to detect a single mutated gene, with the other polymorphic genes per patient, and it is often difficult to determine which of these being of less interest. This goes some way to explaining why, variants underlies disease in a given individual. However, at the despite the abundance of NGS data, the discovery of disease- population level, there may be some degree of phenotypic homo- causing alleles from such data remains somewhat limited. geneity, with alterations of specific physiological pathways under- We developed the human gene connectome (HGC) to over- come this problem.
    [Show full text]